← Back to Clinical Trials
Recruiting NCT07218471

NCT07218471 Cannabis Reduction and Functional Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07218471
Status Recruiting
Phase
Sponsor Medical University of South Carolina
Condition Cannabis Use Disorder
Study Type INTERVENTIONAL
Enrollment 176 participants
Start Date 2026-03-13
Primary Completion 2029-09-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
CBT4CBT (Computerized Cognitive Behavioral Therapy)Motivational InterviewingContingency Management

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 176 participants in total. It began in 2026-03-13 with a primary completion date of 2029-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.

Eligibility Criteria

Inclusion Criteria: * Age 18+ * Urinary cannabinoid level ≥ 50 ng/mL * DSM-5 diagnosis of CUD (mild, moderate, or severe) * Willingness to attempt cannabis reduction * Completion of Intake Visit Exclusion Criteria: * Serious medical/psychiatric conditions * Pregnancy or breastfeeding * Use of cannabis in past 30 days was for medical purposes only * Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition * Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz

Contact & Investigator

Central Contact

Rachel Tomko, PhD

✉ tomko@musc.edu

📞 (843) 792-5447

Principal Investigator

Rachel Tomko, PhD.

PRINCIPAL INVESTIGATOR

Medical University of South Carolina

Frequently Asked Questions

Who can join the NCT07218471 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cannabis Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07218471 currently recruiting?

Yes, NCT07218471 is actively recruiting participants. Contact the research team at tomko@musc.edu for enrollment information.

Where is the NCT07218471 trial being conducted?

This trial is being conducted at Charleston, United States.

Who is sponsoring the NCT07218471 clinical trial?

NCT07218471 is sponsored by Medical University of South Carolina. The principal investigator is Rachel Tomko, PhD. at Medical University of South Carolina. The trial plans to enroll 176 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology